D. Ettinger

Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.
202328 citationsauthor #6
Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases
20231 citationsauthor #8
Large-scale transcriptomic profiling of the tumor immune microenvironment in ALK+ lung cancer.
20231 citationsauthor #9
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer
202311 citationsauthor #21
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
2023379 citationsauthor #1
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
20229 citationsauthor #11
Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation
20229 citationsauthor #20
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
20229 citationsauthor #6
EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
20224 citationsauthor #10
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC
20222 citationsauthor #18
Non – Small Cell Lung Cancer, Version 3.2022
202251 citationsauthor #1
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
202216 citationsauthor #7
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
20221,012 citationsauthor #1
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022.
2022102 citationsauthor #7
296 A comprehensive clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer
20210 citationsauthor #4
Abstract 1668: Longitudinal dynamics of circulating tumor DNA and plasma proteomics predict clinical outcomes to immunotherapy in non-small cell lung cancer
20211 citationsauthor #16
Abstract 27: Early dynamics in peripheral blood immune cell subsets and ctDNA are predictive of outcome to immunotherapy
20210 citationsauthor #15
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
202112 citationsauthor #9
Abstract 538: Liquid biopsy approaches for determining pathologic response to neoadjuvant immunotherapy in esophageal cancer
20210 citationsauthor #11
QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events
20211 citationsauthor #12
Abstract 1617: Sex-specific genomic determinants of response to immunotherapy
20210 citationsauthor #13
MA07.05 Survivors from Anti-PD-(L)1 Immunotherapy in NSCLC: Clinical Features, Survival Outcomes and Long-term Toxicities
20211 citationsauthor #7
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
2021765 citationsauthor #1
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
202113 citationsauthor #6
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
2020172 citationsauthor #21
Lung Metastases
20200 citationsauthor #3
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
2020376 citationsauthor #7
Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.
20201 citationsauthor #12
Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy.
20190 citationsauthor #2
Molecular Alterations in Pulmonary Adenocarcinoma of African Americans.
20193 citationsauthor #4
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
201995 citationsauthor #14
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.
201917 citationsauthor #5
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
2019140 citationsauthor #12
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
2019142 citationsauthor #6
Lung cancer and family-centered concerns
20195 citationsauthor #6
Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes.
20193 citationsauthor #8
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
201916 citationsauthor #4
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy.
201918 citationsauthor #5
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
2019623 citationsauthor #1
Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study.
2018148 citationsauthor #12
Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
20181 citationsauthor #7
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
2018482 citationsauthor #5
NCCN Lung Cancer Screening , Version 3 . 2018 Clinical Practice Guidelines in Oncology
20181 citationsauthor #17
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy.
201817 citationsauthor #7
V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics
201812 citationsauthor #4
Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy.
20181 citationsauthor #6
P3.01-70 Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
20180 citationsauthor #5
Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
2018363 citationsauthor #5
Immune checkpoint inhibition in elderly non-small cell lung cancer patients.
20181 citationsauthor #7
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
2018471 citationsauthor #1
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
201888 citationsauthor #11
Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.
201815 citationsauthor #9
Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience
20176 citationsauthor #5
Pathologic complete response and survival outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: Long-term update of NRG Oncology RTOG 9514 and 0630.
201712 citationsauthor #7
The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade.
20175 citationsauthor #3
MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
201745 citationsauthor #9
Molecular Profiling of Malignant Pleural Effusion in Metastatic Non‐Small‐Cell Lung Carcinoma. The Effect of Preanalytical Factors
201761 citationsauthor #4
P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial
20170 citationsauthor #1
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
2017436 citationsauthor #1
Impact of a Non‐small Cell Lung Cancer Educational Program for Interdisciplinary Teams
201710 citationsauthor #6
NCCN Guidelines Insights: Antiemesis, Version 2.2017.
2017209 citationsauthor #2
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
2017918 citationsauthor #1
MA 09.08 Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1
201720 citationsauthor #8
P2.03a-010 A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC: Topic: Clinical Trials
20170 citationsauthor #7
Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988-2003).
20161 citationsauthor #2
Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.
20167 citationsauthor #1
Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered.
20161 citationsauthor #1
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
2016416 citationsauthor #1
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
201691 citationsauthor #1
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
20169 citationsauthor #7
NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
201525 citationsauthor #9
NCCN Roundtable: What Are the Characteristics of an Optimal Clinical Practice Guideline?
201514 citationsauthor #1
Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival
20158 citationsauthor #4
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
201520 citationsauthor #2
The Impact of Cancer Treatment on the Diets and Food Preferences of Patients Receiving Outpatient Treatment
2015104 citationsauthor #3
Antroquinonol to block Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells.
20150 citationsauthor #4
Non-Small Cell Lung Cancer, Version 6.2015.
2015397 citationsauthor #1
Malignant pleural mesothelioma
20152 citationsauthor #1
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.
2015114 citationsauthor #6
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
201416 citationsauthor #1
Lung cancer screening: has its time come?
20143 citationsauthor #1
NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology
20141 citationsauthor #21
Occult primary, version 3.2014.
201414 citationsauthor #1
Occult primary, version 3.2014; Featured updates to the NCCN guidelines
201424 citationsauthor #1
Non-small cell lung cancer, version 1.2015.
2014168 citationsauthor #1
Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report
201433 citationsauthor #10
Molecular alterations in non-small cell lung carcinomas of the young.
201440 citationsauthor #4
Erratum: Smoking status and survival in the national comprehensive cancer network nonsmall cell lung cancer cohort (Cancer (doi: 10.1002/cncr.27824))
20131 citationsauthor #6
Targeted therapy for non-small-cell lung cancer: past, present and future
2013126 citationsauthor #2
Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors
201344 citationsauthor #2
Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort
201393 citationsauthor #6
Non-small cell lung cancer, version 2.2013.
2013220 citationsauthor #1
Advanced pulmonary carcinoid (APC): 20-year experience at Johns Hopkins (JH).
20131 citationsauthor #4
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines
2013352 citationsauthor #1
Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
2013138 citationsauthor #5
Molecular Alterations in Non Small Cell Lung Cancers of the Young
20130 citationsauthor #3
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.
201395 citationsauthor #1
Clinical Investigation : Thoracic Cancer Phase II Study of Accelerated High-Dose Radiotherapy With Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer : Radiation Therapy Oncology Group Protocol 0239
201243 citationsauthor #3
Lung Cancer and Other Pulmonary Neoplasms
201229 citationsauthor #1
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
20120 citationsauthor #13

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT